Deleterious role of anti-high mobility group box 1 monoclonal antibody in retinal ischemia-reperfusion injury

Shenyang Yang, Kazuyuki Hirooka, Ye Liu, Tomoyoshi Fujita, Kouki Fukuda, Takehiro Nakamutra, Toshifumi Itano, Jiyong Zhang, Masahiro Nishibori, Fumio Shiraga

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: To investigate the effect of anti-high mobility group box 1 (HMGB1) monoclonal antibody (mAb) against ischemia-reperfusion injury in the rat retina. Materials and Methods: Retinal ischemia was induced by increasing and then maintaining intraocular pressure at 130 mmHg for 45min. An intraperitoneal injection of anti-HMGB1 mAb was administered 30min before ischemia. Retinal damage was evaluated at 7 days after the ischemia. Immunohistochemistry and image analysis were used to measure changes in the levels of reactive oxygen species (ROS) and the localization of anti-HMGB1 mAb. Dark-adapted full-field electroretinography (ERG) was also performed. Results: Pretreatment with anti-HMGB1 mAb significantly enhanced the ischemic injury of the retina. HMGB1 expression increased at 612h after ischemia in the retina. After the ischemia, production of ROS was detected in retinal cells. However, pretreatment with anti-HMGB1 mAb increased the production of ROS. On the seventh postoperative day, the amplitudes of both the ERG a-and b-waves were significantly higher in the vehicle group than in the groups pretreated with anti-HMGB1 mAb. Conclusions: The current in vivo model of retinal injury demonstrated that anti-HMGB1 mAb plays a large deleterious role in ischemia-reperfusion injury. In order to develop neuroprotective therapeutic strategies for acute retinal ischemic disorders, further studies on anti-HMGB1 mAb function are needed.

Original languageEnglish
Pages (from-to)1037-1046
Number of pages10
JournalCurrent Eye Research
Volume36
Issue number11
DOIs
Publication statusPublished - Nov 2011

Fingerprint

Reperfusion Injury
Monoclonal Antibodies
Ischemia
Electroretinography
Retina
Reactive Oxygen Species
Wounds and Injuries
Intraperitoneal Injections
Intraocular Pressure
Antibody Formation
Immunohistochemistry

Keywords

  • Anti-HMGB1 mAb
  • Electroretinogram
  • Reactive oxygen species
  • Retinal ischemia
  • Retinal thickness

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Deleterious role of anti-high mobility group box 1 monoclonal antibody in retinal ischemia-reperfusion injury. / Yang, Shenyang; Hirooka, Kazuyuki; Liu, Ye; Fujita, Tomoyoshi; Fukuda, Kouki; Nakamutra, Takehiro; Itano, Toshifumi; Zhang, Jiyong; Nishibori, Masahiro; Shiraga, Fumio.

In: Current Eye Research, Vol. 36, No. 11, 11.2011, p. 1037-1046.

Research output: Contribution to journalArticle

Yang, Shenyang ; Hirooka, Kazuyuki ; Liu, Ye ; Fujita, Tomoyoshi ; Fukuda, Kouki ; Nakamutra, Takehiro ; Itano, Toshifumi ; Zhang, Jiyong ; Nishibori, Masahiro ; Shiraga, Fumio. / Deleterious role of anti-high mobility group box 1 monoclonal antibody in retinal ischemia-reperfusion injury. In: Current Eye Research. 2011 ; Vol. 36, No. 11. pp. 1037-1046.
@article{236935c3a9724670959d1168d95f02ad,
title = "Deleterious role of anti-high mobility group box 1 monoclonal antibody in retinal ischemia-reperfusion injury",
abstract = "Purpose: To investigate the effect of anti-high mobility group box 1 (HMGB1) monoclonal antibody (mAb) against ischemia-reperfusion injury in the rat retina. Materials and Methods: Retinal ischemia was induced by increasing and then maintaining intraocular pressure at 130 mmHg for 45min. An intraperitoneal injection of anti-HMGB1 mAb was administered 30min before ischemia. Retinal damage was evaluated at 7 days after the ischemia. Immunohistochemistry and image analysis were used to measure changes in the levels of reactive oxygen species (ROS) and the localization of anti-HMGB1 mAb. Dark-adapted full-field electroretinography (ERG) was also performed. Results: Pretreatment with anti-HMGB1 mAb significantly enhanced the ischemic injury of the retina. HMGB1 expression increased at 612h after ischemia in the retina. After the ischemia, production of ROS was detected in retinal cells. However, pretreatment with anti-HMGB1 mAb increased the production of ROS. On the seventh postoperative day, the amplitudes of both the ERG a-and b-waves were significantly higher in the vehicle group than in the groups pretreated with anti-HMGB1 mAb. Conclusions: The current in vivo model of retinal injury demonstrated that anti-HMGB1 mAb plays a large deleterious role in ischemia-reperfusion injury. In order to develop neuroprotective therapeutic strategies for acute retinal ischemic disorders, further studies on anti-HMGB1 mAb function are needed.",
keywords = "Anti-HMGB1 mAb, Electroretinogram, Reactive oxygen species, Retinal ischemia, Retinal thickness",
author = "Shenyang Yang and Kazuyuki Hirooka and Ye Liu and Tomoyoshi Fujita and Kouki Fukuda and Takehiro Nakamutra and Toshifumi Itano and Jiyong Zhang and Masahiro Nishibori and Fumio Shiraga",
year = "2011",
month = "11",
doi = "10.3109/02713683.2011.594201",
language = "English",
volume = "36",
pages = "1037--1046",
journal = "Current Eye Research",
issn = "0271-3683",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Deleterious role of anti-high mobility group box 1 monoclonal antibody in retinal ischemia-reperfusion injury

AU - Yang, Shenyang

AU - Hirooka, Kazuyuki

AU - Liu, Ye

AU - Fujita, Tomoyoshi

AU - Fukuda, Kouki

AU - Nakamutra, Takehiro

AU - Itano, Toshifumi

AU - Zhang, Jiyong

AU - Nishibori, Masahiro

AU - Shiraga, Fumio

PY - 2011/11

Y1 - 2011/11

N2 - Purpose: To investigate the effect of anti-high mobility group box 1 (HMGB1) monoclonal antibody (mAb) against ischemia-reperfusion injury in the rat retina. Materials and Methods: Retinal ischemia was induced by increasing and then maintaining intraocular pressure at 130 mmHg for 45min. An intraperitoneal injection of anti-HMGB1 mAb was administered 30min before ischemia. Retinal damage was evaluated at 7 days after the ischemia. Immunohistochemistry and image analysis were used to measure changes in the levels of reactive oxygen species (ROS) and the localization of anti-HMGB1 mAb. Dark-adapted full-field electroretinography (ERG) was also performed. Results: Pretreatment with anti-HMGB1 mAb significantly enhanced the ischemic injury of the retina. HMGB1 expression increased at 612h after ischemia in the retina. After the ischemia, production of ROS was detected in retinal cells. However, pretreatment with anti-HMGB1 mAb increased the production of ROS. On the seventh postoperative day, the amplitudes of both the ERG a-and b-waves were significantly higher in the vehicle group than in the groups pretreated with anti-HMGB1 mAb. Conclusions: The current in vivo model of retinal injury demonstrated that anti-HMGB1 mAb plays a large deleterious role in ischemia-reperfusion injury. In order to develop neuroprotective therapeutic strategies for acute retinal ischemic disorders, further studies on anti-HMGB1 mAb function are needed.

AB - Purpose: To investigate the effect of anti-high mobility group box 1 (HMGB1) monoclonal antibody (mAb) against ischemia-reperfusion injury in the rat retina. Materials and Methods: Retinal ischemia was induced by increasing and then maintaining intraocular pressure at 130 mmHg for 45min. An intraperitoneal injection of anti-HMGB1 mAb was administered 30min before ischemia. Retinal damage was evaluated at 7 days after the ischemia. Immunohistochemistry and image analysis were used to measure changes in the levels of reactive oxygen species (ROS) and the localization of anti-HMGB1 mAb. Dark-adapted full-field electroretinography (ERG) was also performed. Results: Pretreatment with anti-HMGB1 mAb significantly enhanced the ischemic injury of the retina. HMGB1 expression increased at 612h after ischemia in the retina. After the ischemia, production of ROS was detected in retinal cells. However, pretreatment with anti-HMGB1 mAb increased the production of ROS. On the seventh postoperative day, the amplitudes of both the ERG a-and b-waves were significantly higher in the vehicle group than in the groups pretreated with anti-HMGB1 mAb. Conclusions: The current in vivo model of retinal injury demonstrated that anti-HMGB1 mAb plays a large deleterious role in ischemia-reperfusion injury. In order to develop neuroprotective therapeutic strategies for acute retinal ischemic disorders, further studies on anti-HMGB1 mAb function are needed.

KW - Anti-HMGB1 mAb

KW - Electroretinogram

KW - Reactive oxygen species

KW - Retinal ischemia

KW - Retinal thickness

UR - http://www.scopus.com/inward/record.url?scp=80054696106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054696106&partnerID=8YFLogxK

U2 - 10.3109/02713683.2011.594201

DO - 10.3109/02713683.2011.594201

M3 - Article

C2 - 21999229

AN - SCOPUS:80054696106

VL - 36

SP - 1037

EP - 1046

JO - Current Eye Research

JF - Current Eye Research

SN - 0271-3683

IS - 11

ER -